Health
Should AstraZeneca Be Your Next Coronavirus Buy? – The Motley Fool
The drugmaker might well win the coronavirus vaccine race. What would that mean for its stock?
With no end in sight for the coronavirus pandemic, the world is seeing a frantic effort to develop a vaccine for the deadly virus. SARS-CoV-2, the coronavirus responsible for the COVID-19 disease, has taken close to 833,000 lives worldwide. Global recorded cases stand at 24 million, with 5.8 million — and more than 180,000 COVID-related deaths — in the U.S. alone.
AstraZeneca (NYSE:AZN), based in Cambridge, U.K., is working with the University of Oxford to develop its vaccine candidate, AZD12…
-
Business23 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News22 hours agoRent changes on way for hundreds of social housing recipients following government review
-
Business18 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News21 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses